Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis.

摘要: The wide spectrum of clinical manifestations and high relapse rate represent a therapeutic challenge in systemic lupus erythematosus (SLE). Observational studies suggested efficacy rituximab (RTX), B-cell-targeting antibody, to control the activity SLE. Two randomized trials controlled by placebo did not prove superiority RTX when used addition conventional treatment nonrenal (EXPLORER) renal (LUNAR) lupus. A systematic review exploring SLE patients was conducted. pooled percentages response were assessed. Thirty with 1243 analyzed. In using British Isles Lupus Assessment Group (BILAG), complete (CR) 46.7% (95% CI 36.8%-56.8%) partial (PR) 37.9% 30.6%-45.8%). With Systemic Erythematosus Disease Activity Index (SLEDAI), CR 56.6% 32.4%-78.1%) PR 30.9% 8.9%-46%). 36.1% 25.2%-48.6%); 37.4% 28.5%-47.3%). EXPLORER, 12.4% 17.2%; LUNAR 26.4% 30.6%, both cases different from controls. standardization remain challenge. discrepancy perceived between observational reflects heterogeneity stringency criteria response. Further focusing on selected composite indices are warranted.